米食品医薬品局(FDA)がベバシズマブについて、進行卵巣がんの術後化学療法への併用を承認【FDA】

FDA approves bevacizumab in combination with chemotherapy for ovarian cancer

On June 13, 2018, the Food and Drug Administration approved bevacizumab (Avastin, Genentech, Inc.) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.

  

コメント

Leave a comment

Your email address will not be published.


*